PMID- 18797896
OWN - NLM
STAT- MEDLINE
DCOM- 20081211
LR  - 20220409
IS  - 1432-069X (Electronic)
IS  - 0340-3696 (Linking)
VI  - 300
IP  - 10
DP  - 2008 Nov
TI  - Soluble human leukocyte antigen-G and interleukin-10 levels in plasma of 
      psoriatic patients: preliminary study on a possible correlation between 
      generalized immune status, treatments and disease.
PG  - 551-9
LID - 10.1007/s00403-008-0886-6 [doi]
AB  - Human leukocyte antigen (HLA)-G is a non-classical HLA class I molecule that 
      exerts a generalized immunosuppressive action. A deficit in membrane bound and 
      soluble HLA-G levels seems to cause a defective control on immune responses and 
      trigger off several autoimmune diseases. As psoriasis is considered an autoimmune 
      disease, lower levels of soluble HLA-G (sHLA-G) might be expected in psoriatic 
      patients than in healthy controls. The aims of this descriptive study were: (1) 
      to evaluate whether sHLA-G levels are different in psoriatic patients compared to 
      controls; (2) to compare sHLA-G levels between groups of patients treated with 
      different therapies; (3) to evaluate whether any differences found in HLA-G 
      expression could be related to a genetic control. Peripheral blood samples were 
      investigated for sHLA-G and IL-10 levels and for HLA-G 14 bp polymorphism in 65 
      patients with moderate-to-severe plaque psoriasis treated with systemic drugs or 
      with topical or physical treatments and in controls. Significantly lower plasma 
      levels of both sHLA-G and IL-10 were found in psoriatic group compared to 
      controls and in local treated patients in comparison with systemic treated 
      patients. These findings could indicate that low sHLA-G levels may contribute to 
      susceptibility to psoriasis. Absence of differences in HLA-G 14 bp allele and 
      genotype frequencies between psoriatic patients and controls and between patients 
      following different treatments seems to exclude genetic bases of sHLA-G levels. 
      It could be speculated that therapeutics antagonizing systemic T helper 1 
      activation may induce sHLA-G secretion via an IL-10-dependent pathway.
FAU - Borghi, Alessandro
AU  - Borghi A
AD  - Department of Clinical and Experimental Medicine, Section of Dermatology, 
      University of Ferrara, Via Savonarola 9, 44100 Ferrara, Italy.
FAU - Fogli, Emanuela
AU  - Fogli E
FAU - Stignani, Marina
AU  - Stignani M
FAU - Melchiorri, Loredana
AU  - Melchiorri L
FAU - Altieri, Ermete
AU  - Altieri E
FAU - Baricordi, Olavio
AU  - Baricordi O
FAU - Rizzo, Roberta
AU  - Rizzo R
FAU - Virgili, Annarosa
AU  - Virgili A
LA  - eng
PT  - Journal Article
DEP - 20080917
PL  - Germany
TA  - Arch Dermatol Res
JT  - Archives of dermatological research
JID - 8000462
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Dermatologic Agents)
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-G Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 130068-27-8 (Interleukin-10)
RN  - 83HN0GTJ6D (Cyclosporine)
RN  - LCH760E9T7 (Acitretin)
RN  - XX2MN88N5D (efalizumab)
SB  - IM
MH  - Acitretin/therapeutic use
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Case-Control Studies
MH  - Cross-Sectional Studies
MH  - Cyclosporine/therapeutic use
MH  - Dermatologic Agents/therapeutic use
MH  - Female
MH  - Gene Frequency/genetics
MH  - Genotype
MH  - HLA Antigens/*blood
MH  - HLA-G Antigens
MH  - Histocompatibility Antigens Class I/*blood
MH  - Humans
MH  - Immune System/pathology/*physiopathology
MH  - Interleukin-10/*blood
MH  - Male
MH  - Middle Aged
MH  - Polymorphism, Genetic/genetics
MH  - Psoriasis/*blood/drug therapy/genetics
MH  - T-Lymphocytes/pathology
MH  - Young Adult
EDAT- 2008/09/18 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/09/18 09:00
PHST- 2008/04/07 00:00 [received]
PHST- 2008/08/21 00:00 [accepted]
PHST- 2008/07/07 00:00 [revised]
PHST- 2008/09/18 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/09/18 09:00 [entrez]
AID - 10.1007/s00403-008-0886-6 [doi]
PST - ppublish
SO  - Arch Dermatol Res. 2008 Nov;300(10):551-9. doi: 10.1007/s00403-008-0886-6. Epub 
      2008 Sep 17.